Business Context and Reporting Period
Prothena Corporation plc is an Ireland-incorporated, late-stage clinical biotechnology company focused on antibody-based immunotherapies for amyloidosis, neurodegenerative disease and inflammatory disease. This Form 10-K covers the year ended December 31, 2014; the filing was dated March 12, 2015.
- NEOD001: Phase 3 VITAL Amyloidosis Study initiated in December 2014 for newly diagnosed, treatment-naive AL amyloidosis patients with cardiac dysfunction. The program received FDA Fast Track designation in December 2014 and had U.S. and European orphan-drug designations.
- PRX002: Two Phase 1 studies initiated in collaboration with Roche for Parkinson’s disease and related synucleinopathies.
- PRX003: Phase 1 study in healthy volunteers expected to begin in the first half of 2015 for psoriasis and other inflammatory diseases.
Financial Metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $50.9 million | $0.7 million | +7,423% |
| Collaboration revenue | $50.3 million | — | New in 2014 |
| Research and development expense | $38.5 million | $26.1 million | +48% |
| General and administrative expense | $19.1 million | $15.1 million | +27% |
| Total operating expenses | $57.5 million | $41.1 million | +40% |
| Loss from operations | $6.6 million | $40.4 million | Improved |
| Net loss | $7.2 million | $41.0 million | Improved |
| Basic and diluted loss per share | $0.29 | $2.20 | Improved |
| Net cash used in operating activities | $0.7 million | $32.1 million | Improved |
| Cash and cash equivalents at year-end | $293.6 million | $176.7 million | +$116.9 million |
Revenue was primarily driven by the Roche agreement: a $30.0 million upfront payment, a $15.0 million clinical milestone, $6.0 million of development-cost reimbursement and $1.7 million of research-service reimbursement. Under the company’s accounting allocation, $13.3 million of the milestone and $5.3 million of development reimbursement were recognized as collaboration revenue, with $1.7 million recorded as an R&D expense offset.
The operating loss margin was approximately 13.1% of revenue and the net loss margin was approximately 14.1%. These margins benefited substantially from the Roche payments and are not representative of recurring product revenue, because Prothena had no approved commercial products.
At December 31, 2014, total assets were $304.1 million, total liabilities were $14.2 million and shareholders’ equity was $289.9 million. The filing does not report outstanding debt; disclosed liabilities primarily consisted of accounts payable, accrued expenses, taxes and deferred rent.
Material Changes Versus the Prior Comparable Period
- Roche’s license and commercialization agreement became effective in January 2014, producing $45.0 million of upfront and clinical milestone cash payments and substantial collaboration revenue.
- R&D spending increased 48% as PRX002 entered clinical development and manufacturing and clinical-trial activity increased for NEOD001 and other programs.
- G&A spending increased 27%, reflecting higher personnel, consulting and public-company expenses.
- Net loss narrowed to $7.2 million from $41.0 million, principally because of Roche-related revenue.
- Operating cash consumption declined to $0.7 million from $32.1 million, while cash increased by $116.9 million.
- The June and July 2014 equity offerings generated approximately $117.4 million of net proceeds from the issuance of 5,462,500 ordinary shares.
- Shares outstanding increased to 27.4 million at year-end from 21.9 million, primarily due to the 2014 equity offering and option exercises.
- Related-party R&D revenue from Elan declined to $0.5 million and the related R&D Services Agreement expired in December 2014; no related-party revenue was expected in 2015.
Guidance, Outlook, Risks and Unusual Items
- Management expected 2015 R&D expense to increase, primarily because of the NEOD001 Phase 3 program and continued PRX002 development and manufacturing cost-sharing with Roche.
- Management expected 2015 G&A expense to increase moderately due to additional personnel, legal and administrative costs.
- Management believed existing cash and cash equivalents would fund obligations for at least the next twelve months, but stated that additional capital would likely be required for continued development and eventual commercialization.
- Roche is primarily responsible for PRX002 development, regulatory approval and commercialization outside the United States. In the United States, Prothena may bear 30% of development and commercialization costs and receive 30% of profits or losses if it remains opted in.
- Roche may terminate the agreement at will after the first anniversary, subject to notice requirements. Future milestone and royalty payments are contingent on clinical, regulatory and commercial success and are not assured.
- NEOD001 Phase 1/2 data showed cardiac responses in 7 of 14 evaluable patients and renal responses in 6 of 14 evaluable patients; these were early, non-randomized data and may not predict Phase 3 results.
- The company expects continuing losses and has no approved products or product sales. Clinical, regulatory, manufacturing, reimbursement and commercialization outcomes remain uncertain.
- Prothena depends on third parties, including Boehringer Ingelheim for clinical supplies and contract research organizations for clinical-trial execution.
- Contractual obligations totaled approximately $16.8 million, including $12.1 million of operating leases, $3.2 million of purchase commitments and $1.5 million under license agreements. Future Roche cost-sharing obligations were not determinable.
- The company disclosed no material legal proceedings and no off-balance-sheet arrangements.
- A significant personnel risk was disclosed: CEO Dale Schenk had been diagnosed with pancreatic cancer and was undergoing treatment.
Most Important Facts for an Investor to Verify
- Whether NEOD001’s Phase 3 VITAL study achieves its mortality or cardiac-hospitalization endpoint and whether the early biomarker results translate into clinical benefit.
- PRX002 Phase 1 safety, pharmacokinetic and biomarker results, and Roche’s continued financial and operational commitment.
- The company’s cash runway after higher Phase 3 spending, including the timing and terms of any future financing.
- The recurring versus non-recurring components of 2014 collaboration revenue and the limited visibility into future Roche milestones, royalties and profit sharing.
- Clinical supply capacity and manufacturing compliance, particularly the company’s dependence on Boehringer Ingelheim and other third parties.
- Progress and safety data for PRX003 and the broader discovery pipeline.
- The potential impact of additional equity issuance, outstanding options and future share-based compensation on dilution.